CoChat
Sign Up
Cited by 23

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Anti-c-myc RNAi-Based Onconanotherapeutics

Habib, Saffiya, Ariatti, Mario, Singh, Moganavelli·2020·Biomedicines
DOI 10.3390/biomedicines8120612PMC PMC7765184
Open this paper in CoChat — free account

Abstract

Overexpression of the c-myc proto-oncogene features prominently in most human cancers. Early studies established that inhibiting the expression of oncogenic c-myc, produced potent anti-cancer effects. This gave rise to the notion that an appropriate c-myc silencing agent might provide a broadly applicable and more effective form of cancer treatment than is currently available. The endogenous mechanism of RNA interference (RNAi), through which small RNA molecules induce gene silencing by binding to complementary mRNA transcripts, represents an attractive avenue for c-myc inhibition. However, the development of a clinically viable, anti-c-myc RNAi-based platform is largely dependent upon the design of an appropriate carrier of the effector nucleic acids. To date, organic and inorganic nanoparticles were assessed both in vitro and in vivo, as carriers of small interfering RNA (siRNA), DICER-substrate siRNA (DsiRNA), and short hairpin RNA (shRNA) expression plasmids, directed against the c-myc oncogene. We review here the various anti-c-myc RNAi-based nanosystems that have come to the fore, especially between 2005 and 2020.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biomedicines8120612

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Transcription of the c-myc gene in normal cells occurs in response to signals from membrane-anchored receptors. White arrows show the direction of transcription (adapted from [18]).
Figure 1 Transcription of the c-myc gene in normal cells occurs in response to signals from membrane-anchored receptors. White arrows show the direction of transcription (adapted from [18]).CC BY · PubMed Central
Figure 2 Lipid-based delivery agents for anti-c-myc siRNA (a) pegylated, neutral liposome, (b) cationic liposome, (c) liposome-polycation-DNA (LPD) nanoparticle, and (d) lipid calcium phosphate (LCP) nanoparticle. Images were created using DesignSpark Mechanical 2.0 software.
Figure 2 Lipid-based delivery agents for anti-c-myc siRNA (a) pegylated, neutral liposome, (b) cationic liposome, (c) liposome-polycation-DNA (LPD) nanoparticle, and (d) lipid calcium phosphate (LCP) nanoparticle. Images were created using DesignSpark Mechanical 2.0 software.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 111

  1. Zeller, 2006, Global mapping of c-Myc binding sites and target gene networks in human B cells, Proc. Natl. Acad. Sci. USA, 103, 17834, 10.1073/pnas.0604129103 · DOI
  2. Berns, 1997, Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity, Oncogene, 15, 1347, 10.1038/sj.onc.1201280 · DOI
  3. Hermeking, 2000, Identification of CDK4 as a target of c-MYC, Proc. Natl. Acad. Sci. USA, 97, 2229, 10.1073/pnas.050586197 · DOI
  4. Kim, 2004, Evaluation of Myc E-Box Phylogenetic Footprints in Glycolytic Genes by Chromatin Immunoprecipitation Assays, Mol. Cell. Biol., 24, 5923, 10.1128/MCB.24.13.5923-5936.2004 · DOI · Paper page
  5. Liu, Y.-C., Li, F., Handler, J., Huang, C.R.L., Xiang, Y., Neretti, N., Sedivy, J.M., I Zeller, K., and Dang, C.V. (2008). Global Regulation of Nucleotide Biosynthetic Genes by c-Myc. PLoS ONE, 3. · DOI · Paper page
  6. Schuhmacher, 1999, Control of cell growth by c-Myc in the absence of cell division, Curr. Biol., 9, 1255, 10.1016/S0960-9822(99)80507-7 · DOI
  7. Wilson, 2004, c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation, Genes Dev., 18, 2747, 10.1101/gad.313104 · DOI · Paper page
  8. Morrish, 2003, c-MYC apoptotic function is mediated by NRF-1 target genes, Genes Dev., 17, 240, 10.1101/gad.1032503 · DOI
  9. Eick, 1986, Transcriptional arrest within the first exon is a fast control mechanism in c-myc gene expression, Nucleic Acids Res., 14, 8331, 10.1093/nar/14.21.8331 · DOI
  10. Bentley, 1986, Novel promoter upstream of the human c-myc gene and regulation of c-myc expression in B-cell lymphomas, Mol. Cell. Biol., 6, 3481
  11. Culjkovic, 2006, eIF4E is a central node of an RNA regulon that governs cellular proliferation, J. Cell Biol., 175, 415, 10.1083/jcb.200607020 · DOI
  12. Dani, 1984, Extreme instability of myc mRNA in normal and transformed human cells, Proc. Natl. Acad. Sci. USA, 81, 7046, 10.1073/pnas.81.22.7046 · DOI
  13. Vervoorts, 2006, The Ins and Outs of MYC Regulation by Posttranslational Mechanisms, J. Biol. Chem., 281, 34725, 10.1074/jbc.R600017200 · DOI
  14. Dai, 2009, Inhibition of c-Myc activity by ribosomal protein L11, EMBO J., 28, 993, 10.1038/emboj.2009.70 · DOI
  15. Grandori, 2000, The Myc/Max/Mad Network and the Transcriptional Control of Cell Behavior, Annu. Rev. Cell Dev. Biol., 16, 653, 10.1146/annurev.cellbio.16.1.653 · DOI · Paper page
  16. Dang, 2012, MYC on the Path to Cancer, Cell, 149, 22, 10.1016/j.cell.2012.03.003 · DOI · Paper page
  17. Battey, 1983, The human c-myc oncogene: Structural consequences of translocation into the igh locus in Burkitt lymphoma, Cell, 34, 779, 10.1016/0092-8674(83)90534-2 · DOI
  18. Martinotti, 1983, Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas, Science, 219, 963, 10.1126/science.6401867 · DOI
  19. Treszl, 2004, Extra copies of c-mycare more pronounced in nodular melanomas than in superficial spreading melanomas as revealed by fluorescence in situ hybridisation, Cytom. Part B Clin. Cytom., 60, 37, 10.1002/cyto.b.20016 · DOI
  20. Smith, 1993, Over-expression of the c-myc proto-oncogene in colorectal carcinoma, Br. J. Cancer, 68, 407, 10.1038/bjc.1993.350 · DOI
  21. Adams, 1985, The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice, Nat. Cell Biol., 318, 533
  22. Leder, 1986, Consequences of widespread deregulation of the c-myc gene in transgenic mice: Multiple neoplasms and normal development, Cell, 45, 485, 10.1016/0092-8674(86)90280-1 · DOI
  23. Li, 1999, c-Myc Overexpression Uncouples DNA Replication from Mitosis, Mol. Cell. Biol., 19, 5339, 10.1128/MCB.19.8.5339 · DOI
  24. Gil, 2005, Immortalization of Primary Human Prostate Epithelial Cells by c-Myc, Cancer Res., 65, 2179, 10.1158/0008-5472.CAN-03-4030 · DOI
  25. Kuzyk, 2014, c-MYC-Induced Genomic Instability, Cold Spring Harb. Perspect. Med., 4, a014373, 10.1101/cshperspect.a014373 · DOI
  26. Vaux, 1988, Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells, Nat. Cell Biol., 335, 440
  27. Wang, 2011, Reviewing once more the c-myc and Ras collaboration, Cell Cycle, 10, 57, 10.4161/cc.10.1.14449 · DOI
  28. Arvanitis, 2006, Conditional transgenic models define how MYC initiates and maintains tumorigenesis, Semin. Cancer Biol., 16, 313, 10.1016/j.semcancer.2006.07.012 · DOI
  29. Felsher, 2010, MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms, Genes Cancer, 1, 597, 10.1177/1947601910377798 · DOI
  30. Soucek, 2008, Modelling Myc inhibition as a cancer therapy, Nat. Cell Biol., 455, 679
  31. Holt, 1988, An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation, Mol. Cell. Biol., 8, 963
  32. Loke, 1988, Delivery of c-myc Antisense Phosphorothioate Oligodeoxynucleotides to Hematopoietic Cells in Culture by Liposome Fusion: Specific Reduction in c-myc Protein Expression Correlates with Inhibition of Cell Growth and DNA Synthesis, Endogenous ADP-Ribosylation, 141, 282
  33. Wickstrom, 1988, Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA, Proc. Natl. Acad. Sci. USA, 85, 1028, 10.1073/pnas.85.4.1028 · DOI
  34. Cutrona, 2003, Inhibition of the translocated c-myc in Burkitt’s lymphoma by a PNA Complementary to the Eμ Enhancer, Cancer Res., 63, 6144
  35. Hudziak, 2000, Antiproliferative Effects of Steric Blocking Phosphorodiamidate Morpholino Antisense Agents Directed against c-myc, Antisense Nucleic Acid Drug Dev., 10, 163, 10.1089/oli.1.2000.10.163 · DOI
  36. Fire, 1998, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature, 391, 806, 10.1038/35888 · DOI · Paper page
  37. Elbashir, 2001, RNA interference is mediated by 21- and 22-nucleotide RNAs, Genes Dev., 15, 188, 10.1101/gad.862301 · DOI
  38. Kim, 2005, Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy, Nat. Biotechnol., 23, 222, 10.1038/nbt1051 · DOI
  39. Ambesajir, 2012, RNA interference: A futuristic tool and its therapeutic applications, Saudi J. Biol. Sci., 19, 395, 10.1016/j.sjbs.2012.08.001 · DOI
  40. Taxman, 2010, Short Hairpin RNA (shRNA): Design, Delivery, and Assessment of Gene Knockdown, Structural Genomics and Drug Discovery, Volume 629, 139
  41. Cao, 2009, Construction of small interfering RNA targeting mouse vascular endothelial growth factor receptor-2: Its serum stability and gene silencing efficiency in vitro, J. South. Med. Univ., 29, 864
  42. Huang, 2011, Elimination Pathways of Systemically Delivered siRNA, Mol. Ther., 19, 381, 10.1038/mt.2010.266 · DOI
  43. Hoerter, 2007, Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum, RNA, 13, 1887, 10.1261/rna.602307 · DOI
  44. Allison, 2014, RNA Interference by Single- and Double-stranded siRNA with a DNA Extension Containing a 3′ Nuclease-resistant Mini-hairpin Structure, Mol. Ther. Nucl. Acids, 2, e141, 10.1038/mtna.2013.68 · DOI
  45. Akhtar, 2007, Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity, Adv. Drug Deliv. Rev., 59, 164, 10.1016/j.addr.2007.03.010 · DOI
  46. Wang, 2010, Delivery of siRNA Therapeutics: Barriers and Carriers, AAPS J., 12, 492, 10.1208/s12248-010-9210-4 · DOI
  47. Batzri, 1973, Single bilayer liposomes prepared without sonication, Biochim. Biophys. Acta (BBA) Biomembr., 298, 1015, 10.1016/0005-2736(73)90408-2 · DOI
  48. Mangala, 2015, Targeting c-MYC in Platinum-Resistant Ovarian Cancer, Mol. Cancer Ther., 14, 2260, 10.1158/1535-7163.MCT-14-0801 · DOI
  49. Suk, 2016, PEGylation as a strategy for improving nanoparticle-based drug and gene delivery, Adv. Drug Deliv. Rev., 99, 28, 10.1016/j.addr.2015.09.012 · DOI · Paper page
  50. Felgner, 1987, Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure, Proc. Natl. Acad. Sci. USA, 84, 7413, 10.1073/pnas.84.21.7413 · DOI
  51. Khatri, 2014, Development and Characterization of siRNA Lipoplexes: Effect of Different Lipids, In Vitro Evaluation in Cancerous Cell Lines and In Vivo Toxicity Study, AAPS PharmSciTech, 15, 1630, 10.1208/s12249-014-0193-9 · DOI
  52. Zhang, 2009, The knockdown of c-myc expression by RNAi inhibits cell proliferation in human colon cancer HT-29 cells in vitro and in vivo, Cell. Mol. Biol. Lett., 14, 305, 10.2478/s11658-009-0001-9 · DOI · Paper page
  53. Habib, 2020, Anti-c-myc cholesterol based lipoplexes as onco-nanotherapeutic agents in vitro, F1000Research, 9, 770, 10.12688/f1000research.25142.1 · DOI
  54. Chen, 2010, Nanoparticles Targeted With NGR Motif Deliver c-myc siRNA and Doxorubicin for Anticancer Therapy, Mol. Ther., 18, 828, 10.1038/mt.2009.291 · DOI
  55. Zhang, 2013, Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy, Biomaterials, 34, 8459, 10.1016/j.biomaterials.2013.07.050 · DOI
  56. Yang, 2015, Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting delivery, Biomaterials, 48, 84, 10.1016/j.biomaterials.2015.01.030 · DOI
  57. Xie, 2016, Efficient siRNA Delivery Using Novel Cell-Penetrating Peptide-siRNA Conjugate-Loaded Nanobubbles and Ultrasound, Ultrasound Med. Biol., 42, 1362, 10.1016/j.ultrasmedbio.2016.01.017 · DOI
  58. Song, 2005, Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors, Nat. Biotechnol., 23, 709, 10.1038/nbt1101 · DOI
  59. Li, 2008, Efficient Oncogene Silencing and Metastasis Inhibition via Systemic Delivery of siRNA, Mol. Ther., 16, 942, 10.1038/mt.2008.51 · DOI
  60. Yang, 2012, Systemic Delivery of siRNA via LCP Nanoparticle Efficiently Inhibits Lung Metastasis, Mol. Ther., 20, 609, 10.1038/mt.2011.270 · DOI
  61. Yang, 2012, Nanoparticle Delivery of Pooled siRNA for Effective Treatment of Non-Small Cell Lung Caner, Mol. Pharm., 9, 2280, 10.1021/mp300152v · DOI
  62. Lunavat, 2016, RNAi delivery by exosome-mimetic nanovesicles–Implications for targeting c-Myc in cancer, Biomaterials, 102, 231, 10.1016/j.biomaterials.2016.06.024 · DOI
  63. Li, 2017, Dual Tumor-Targeting Nanocarrier System for siRNA Delivery Based on pRNA and Modified Chitosan, Mol. Ther. Nucleic Acids, 8, 169, 10.1016/j.omtn.2017.06.014 · DOI
  64. Raichur, 2015, Strategist PLGA Nano-capsules to Deliver siRNA for Inhibition of Carcinoma and Neuroblastoma Cell Lines by Knockdown of MYC Proto-oncogene using CPPs and PNA, NanoWorld J., 1, 32, 10.17756/nwj.2015-005 · DOI
  65. Misra, 2018, Nano-Assembly of Pamitoyl-Bioconjugated Coenzyme-A for Combinatorial Chemo-Biologics in Transcriptional Therapy, Bioconjugate Chem., 29, 1419, 10.1021/acs.bioconjchem.8b00117 · DOI
  66. Ruan, 2016, Topical and Targeted Delivery of siRNAs to Melanoma Cells Using a Fusion Peptide Carrier, Sci. Rep., 6, 29159, 10.1038/srep29159 · DOI
  67. Bjorge, J.D., Pang, A., and Fujita, D.J. (2017). Delivery of gene targeting siRNAs to breast cancer cells using a multifunctional peptide complex that promotes both targeted delivery and endosomal release. PLoS ONE, 12. · DOI
  68. Yang, 2016, Dual stimulus of hyperthermia and intracellular redox environment triggered release of siRNA for tumor-specific therapy, Int. J. Pharm., 506, 158, 10.1016/j.ijpharm.2016.04.035 · DOI
  69. Yang, 2016, Thermal and magnetic dual-responsive liposomes with a cell-penetrating peptide-siRNA conjugate for enhanced and targeted cancer therapy, Colloids Surf. B Biointerfaces, 146, 607, 10.1016/j.colsurfb.2016.07.002 · DOI
  70. Chaudhary, 2014, Surface functionalized selenium nanoparticles for biomedical applications, J. Biomed. Nanotechnol., 10, 3004, 10.1166/jbn.2014.1985 · DOI
  71. Fraga, 2014, Short- and long-term distribution and toxicity of gold nanoparticles in the rat after a single-dose intravenous administration, Nanomed. Nanotechnol. Biol. Med., 10, 1757, 10.1016/j.nano.2014.06.005 · DOI
  72. Zhou, 2009, Functionalized gold nanoparticles: Synthesis, structure and colloid stability, J. Colloid Interface Sci., 331, 251, 10.1016/j.jcis.2008.12.002 · DOI · Paper page
  73. Maiyo, F., and Singh, M. (2020). Polymerized Selenium Nanoparticles for Folate-Receptor-Targeted Delivery of Anti-Luc-siRNA: Potential for Gene Silencing. Biomaterials, 8. · DOI
  74. Mbatha, 2019, Dendrimer functionalized folate-targeted gold nanoparticles for luciferase gene silencing in vitro: A proof of principle study, Acta Pharm., 69, 49, 10.2478/acph-2019-0008 · DOI
  75. Conde, 2012, Design of Multifunctional Gold Nanoparticles for In Vitro and In Vivo Gene Silencing, ACS Nano, 6, 8316, 10.1021/nn3030223 · DOI
  76. Xia, 2018, siRNA-loaded selenium nanoparticle modified with hyaluronic acid for enhanced hepatocellular carcinoma therapy, Int. J. Nanomed., 13, 1539, 10.2147/IJN.S157519 · DOI
  77. McCully, 2015, Significance of the balance between intracellular glutathione and polyethylene glycol for successful release of small interfering RNA from gold nanoparticles, Nano Res., 8, 3281, 10.1007/s12274-015-0828-5 · DOI
  78. Shaat, 2016, Modified gold nanoparticles for intracellular delivery of anti-liver cancer siRNA, Int. J. Pharm., 504, 125, 10.1016/j.ijpharm.2016.03.051 · DOI
  79. Daniels, 2019, Sterically stabilized siRNA:gold nanocomplexes enhance c-MYC silencing in a breast cancer cell model, Nanomedicine, 14, 1387, 10.2217/nnm-2018-0462 · DOI
  80. Kim, 2017, Atom Transfer Radical Polymerization of Multishelled Cationic Corona for the Systemic Delivery of siRNA, Nano Lett., 18, 314, 10.1021/acs.nanolett.7b04183 · DOI
  81. Mao, W., Lee, S., Shin, J.U., and Yoo, H.S. (2020). Surface-Initiated Atom Transfer Polymerized Anionic Corona on Gold Nanoparticles for Anti-Cancer Therapy. Pharmaceutics, 12. · DOI
  82. Conde, 2015, RNAi-based glyconanoparticles trigger apoptotic pathways for in vitro and in vivo enhanced cancer-cell killing, Nanoscale, 7, 9083, 10.1039/C4NR05742B · DOI
  83. Conde, 2013, In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models, Biomaterials, 34, 7744, 10.1016/j.biomaterials.2013.06.041 · DOI
  84. Huang, 2018, Therapeutic nanosystems co-deliver anticancer drugs and oncogene SiRNA to achieve synergetic precise cancer chemo-gene therapy, J. Mater. Chem. B, 6, 3013, 10.1039/C8TB00004B · DOI
  85. Imani, 2018, Polyethylene glycol and octa-arginine dual-functionalized nanographene oxide: An optimization for efficient nucleic acid delivery, Biomater. Sci., 6, 1636, 10.1039/C8BM00058A · DOI
  86. Nundkumar, 2020, Amino Acid Functionalized Hydrotalcites for Gene Silencing, J. Nanosci. Nanotechnol., 20, 3387, 10.1166/jnn.2020.17420 · DOI
  87. Tolcher, 2015, Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors, J. Clin. Oncol., 33, 11006, 10.1200/jco.2015.33.15_suppl.11006 · DOI
  88. Whitfield, 2017, Strategies to Inhibit Myc and Their Clinical Applicability, Front. Cell Dev. Biol., 5, 10, 10.3389/fcell.2017.00010 · DOI
  89. Wang, 2004, Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo, Breast Cancer Res., 7, R220, 10.1186/bcr975 · DOI
  90. Zhao, 2013, RNAi silencing of c-Myc inhibits cell migration, invasion, and proliferation in HepG2 human hepatocellular carcinoma cell line: C-Myc silencing in hepatocellular carcinoma cell, Cancer Cell Int., 13, 23, 10.1186/1475-2867-13-23 · DOI
  91. Huang, 2008, siRNA directed against c-Myc inhibits proliferation and downregulates human telomerase reverse transcriptase in human colon cancer Colo 320 cells, J. Exp. Clin. Cancer Res., 27, 27, 10.1186/1756-9966-27-27 · DOI
  92. Song, 2011, Effects of RNA interference targeting four different genes on the growth and proliferation of nasopharyngeal carcinoma CNE-2Z cells, Cancer Gene Ther., 18, 297, 10.1038/cgt.2010.80 · DOI
  93. Tai, 2012, Effects of siRNA Targeting c-Myc and VEGF on Human Colorectal Cancer Volo Cells, J. Biochem. Mol. Toxicol., 26, 499, 10.1002/jbt.21455 · DOI
  94. Cheng, 2020, Building Customizable Multisite-Targeting c-Myc shRNA Array into Branch-PCR-Constructed DNA Nanovectors for Enhanced Tumor Cell Suppression, ChemistrySelect, 5, 10250, 10.1002/slct.202002609 · DOI
  95. Tangudu, 2015, RNA Interference Using c-Myc-Conjugated Nanoparticles Suppresses Breast and Colorectal Cancer Models, Mol. Cancer Ther., 14, 1259, 10.1158/1535-7163.MCT-14-0970 · DOI
  96. Moodley, T., and Singh, M. (2019). Polymeric Mesoporous Silica Nanoparticles for Enhanced Delivery of 5-Fluorouracil In Vitro. Pharmaceutics, 11. · DOI
  97. Moodley, T., and Singh, M. (2020). Sterically Stabilised Polymeric Mesoporous Silica Nanoparticles Improve Doxorubicin Efficiency: Tailored Cancer Therapy. Molecules, 25. · DOI
  98. Mngadi, S., Mokhosi, S., Singh, M., and Mdlalose, W. (2020). Chitosan-Functionalized Mg0.5Co0.5Fe2O4 Magnetic Nanoparticles Enhance Delivery of 5-Fluorouracil In Vitro. Coatings, 10. · DOI
  99. (2019). Synthesis and characterization of magnetic nanoparticles of cobalt ferrite coated with silica. Biointerface Res. Appl. Chem., 10, 4908–4913. · DOI
  100. Takahashi, 2009, Quantitative and Temporal Analysis of Gene Silencing in Tumor Cells Induced by Small Interfering RNA or Short Hairpin RNA Expressed from Plasmid Vectors, J. Pharm. Sci., 98, 74, 10.1002/jps.21398 · DOI
  101. Xu, 2015, Delivery systems for siRNA drug development in cancer therapy, Asian J. Pharm. Sci., 10, 1, 10.1016/j.ajps.2014.08.011 · DOI
  102. Boettcher, 2015, Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR, Mol. Cell, 58, 575, 10.1016/j.molcel.2015.04.028 · DOI
  103. Unniyampurath, U., Pilankatta, R., and Krishnan, M.N. (2016). RNA Interference in the Age of CRISPR: Will CRISPR Interfere with RNAi?. Int. J. Mol. Sci., 17. · DOI
  104. Gabay, 2014, MYC Activation Is a Hallmark of Cancer Initiation and Maintenance, Cold Spring Harb. Perspect. Med., 4, a014241, 10.1101/cshperspect.a014241 · DOI
  105. Kanamaru, 1998, Biological Effects and Cellular Uptake of c-mycAntisense Oligonucleotides and Their Cationic Liposome Complexes, J. Drug Target., 5, 235, 10.3109/10611869808995878 · DOI
  106. Putney, 1999, Enhanced Anti-Tumor Effects with Microencapsulated c-mycAntisense Oligonucleotide, Antisense Nucleic Acid Drug Dev., 9, 451, 10.1089/oli.1.1999.9.451 · DOI
  107. Carroll, 2002, Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: Implications for the antiproliferative effects of antiestrogens, Cancer Res., 62, 3126
  108. Pan, 2015, A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy, Nanomedicine, 10, 241, 10.2217/nnm.14.101 · DOI
  109. Soodgupta, 2015, Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma, Mol. Cancer Ther., 14, 1286, 10.1158/1535-7163.MCT-14-0774-T · DOI
  110. Esser, 2020, Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer, Theranostics, 10, 7510, 10.7150/thno.44523 · DOI
  111. Sajid, M.I., Moazzam, M., Kato, S., Cho, K.Y., and Tiwari, R.K. (2020). Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside. Pharmaceutics, 13. · DOI

Cited by

Sorted by citations

Metadata

Authors
Habib, S., Ariatti, M., & Singh, M.
Venue
Biomedicines
Publisher
MDPI AG
Published
2020-12-15
Volume
8
Issue
12
Pages
612
ISSN
2227-9059
DOI
10.3390/biomedicines8120612
PMC
PMC7765184
Cited by
23
References
3
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
National Research Foundation of South Africa (113850 and 120455)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review